{"id":"lymphoseek","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Injection site irritation","drugRate":"0.7%","severity":"common","organSystem":""},{"effect":"Injection site pain","drugRate":"0.2%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL5315077","moleculeType":"Small molecule"},"aliases":["99mTc-Diethylenetriamine Pentaacetic Acid-Mannosyl-Dextran","99mTc-DTPA-Mannosyl-Dextran","Technetium Tc 99m-labeled Tilmanocept","technetium Tc 99m tilmanocept","Tc-99m Tilmanocept (Lymphoseek)"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Lymphoseek","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:19:05.951147+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:19:20.325048+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:19:11.453751+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lymphoseek","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:19:11.815839+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5315077/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:19:12.501120+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"72f31b09-4d7b-475c-b37a-9daf2ad80240","title":"KIT FOR THE PREPARATION OF LYMPHOSEEK (TECHNETIUM TC 99M TILMANOCEPT) (TILMANOCEPT) KIT [CARDINAL HEALTH 414, LLC]"},"aiSummary":"Lymphoseek is a marketed diagnostic aid developed by Eben Rosenthal, currently holding a niche position in the diagnostic imaging market. Its key strength lies in its unique mechanism of action, which differentiates it from other diagnostic tools. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.","ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-27T23:53:35.834Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:19:20.325186+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Diagnostic aid","diseaseId":"diagnostic-aid","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":"Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8","enrollment":50},{"nctId":"NCT03157167","phase":"PHASE1","title":"An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-01","conditions":"Kaposi Sarcoma, HIV Infections","enrollment":15},{"nctId":"NCT05246280","phase":"PHASE3","title":"Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2022-03-02","conditions":"Rheumatoid Arthritis","enrollment":169},{"nctId":"NCT04947137","phase":"PHASE2","title":"Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2021-05-27","conditions":"Rheumatoid Arthritis","enrollment":134},{"nctId":"NCT04078191","phase":"PHASE2","title":"Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2021-09-14","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT03332940","phase":"PHASE1","title":"Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-06","conditions":"Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis","enrollment":6},{"nctId":"NCT04498221","phase":"NA","title":"Lymphatic Mapping Of Oropharyngeal Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-07-07","conditions":"Oropharyngeal Cancer","enrollment":150},{"nctId":"NCT02509598","phase":"PHASE2","title":"A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping","status":"COMPLETED","sponsor":"Cardinal Health 414, LLC","startDate":"2015-08","conditions":"Rhabdomyosarcoma, Melanoma","enrollment":24},{"nctId":"NCT05236387","phase":"","title":"Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2022-03-01","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT04096716","phase":"PHASE1","title":"Mapping Draining Lymph Nodes in CNS Malignancies","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2019-12-03","conditions":"Central Nervous System Neoplasms, Central Nervous System Tumor","enrollment":14},{"nctId":"NCT04663126","phase":"EARLY_PHASE1","title":"Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma","status":"TERMINATED","sponsor":"John O. Prior","startDate":"2021-02-01","conditions":"Melanoma","enrollment":5},{"nctId":"NCT04511026","phase":"PHASE2","title":"Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2021-01-20","conditions":"Endometrial Cancer","enrollment":6},{"nctId":"NCT03938636","phase":"PHASE2","title":"Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2019-04-08","conditions":"Rheumatoid Arthritis","enrollment":116},{"nctId":"NCT03405142","phase":"PHASE2","title":"Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer","status":"COMPLETED","sponsor":"Eben Rosenthal","startDate":"2019-08-01","conditions":"Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Head and Neck Cancer","enrollment":3},{"nctId":"NCT01902953","phase":"PHASE2","title":"Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)","status":"COMPLETED","sponsor":"Maimonides Medical Center","startDate":"2013-03","conditions":"Colon Cancer, Rectal Cancer","enrollment":16},{"nctId":"NCT03029988","phase":"PHASE1","title":"An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-07-26","conditions":"Liver Metastases, Colorectal Carcinoma","enrollment":3},{"nctId":"NCT02287675","phase":"PHASE4","title":"Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Kettering Health Network","startDate":"2015-01-19","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04261179","phase":"PHASE4","title":"Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer","status":"UNKNOWN","sponsor":"Anna Cruceta","startDate":"2020-03","conditions":"Head Cancer, Neck Cancer, Melanoma","enrollment":30},{"nctId":"NCT02683421","phase":"PHASE1","title":"Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2016-07","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT02065232","phase":"","title":"Sentinel Lymph Node Mapping Post-Injection Site Pain","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-03","conditions":"Breast Cancer","enrollment":52},{"nctId":"NCT02509585","phase":"PHASE2","title":"A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection","status":"TERMINATED","sponsor":"Cardinal Health 414, LLC","startDate":"2016-01","conditions":"Uterine Cervical Neoplasms","enrollment":18},{"nctId":"NCT02589366","phase":"PHASE1","title":"Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2015-11","conditions":"Endometrial Cancer","enrollment":2},{"nctId":"NCT03199560","phase":"PHASE4","title":"Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy","status":"UNKNOWN","sponsor":"Memorial Health University Medical Center","startDate":"2017-06-22","conditions":"Sentinel Lymph Node Biopsy, Breast Cancer","enrollment":86},{"nctId":"NCT02857608","phase":"PHASE2","title":"A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus","status":"WITHDRAWN","sponsor":"Cardinal Health 414, LLC","startDate":"2016-09","conditions":"Anal Cancer","enrollment":""},{"nctId":"NCT02201420","phase":"PHASE2","title":"Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2014-09","conditions":"Kaposi's Sarcoma","enrollment":5},{"nctId":"NCT00911326","phase":"PHASE3","title":"Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2009-05","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":101},{"nctId":"NCT01106040","phase":"PHASE3","title":"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2010-06","conditions":"Breast Cancer, Melanoma","enrollment":163},{"nctId":"NCT00671918","phase":"PHASE3","title":"Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2008-04","conditions":"Breast Cancer, Melanoma","enrollment":186}],"_emaApprovals":[],"_faersSignals":[{"count":123,"reaction":"DRUG INEFFECTIVE"},{"count":47,"reaction":"OFF LABEL USE"},{"count":14,"reaction":"INJECTION SITE PAIN"},{"count":12,"reaction":"RASH"},{"count":5,"reaction":"MEDICATION ERROR"},{"count":4,"reaction":"ERYTHEMA"},{"count":4,"reaction":"PRODUCT PREPARATION ERROR"},{"count":4,"reaction":"RADIOISOTOPE UPTAKE INCREASED"},{"count":3,"reaction":"DRUG DISPENSING ERROR"},{"count":3,"reaction":"INCORRECT DOSE ADMINISTERED"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL5315077"},"formularyStatus":[],"_approvalHistory":[{"date":"20150803","type":"SUPPL","sponsor":"CARDINAL HEALTH 414","applicationNumber":"NDA202207"},{"date":"20141014","type":"SUPPL","sponsor":"CARDINAL HEALTH 414","applicationNumber":"NDA202207"},{"date":"20190708","type":"SUPPL","sponsor":"CARDINAL HEALTH 414","applicationNumber":"NDA202207"},{"date":"20161020","type":"SUPPL","sponsor":"CARDINAL HEALTH 414","applicationNumber":"NDA202207"},{"date":"20140613","type":"SUPPL","sponsor":"CARDINAL HEALTH 414","applicationNumber":"NDA202207"},{"date":"20130313","type":"ORIG","sponsor":"CARDINAL HEALTH 414","applicationNumber":"NDA202207"},{"date":"20210519","type":"SUPPL","sponsor":"CARDINAL HEALTH 414","applicationNumber":"NDA202207"},{"date":"20161130","type":"SUPPL","sponsor":"CARDINAL HEALTH 414","applicationNumber":"NDA202207"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":23,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Lymphoseek","genericName":"Lymphoseek","companyName":"Eben Rosenthal","companyId":"eben-rosenthal","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":3},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:19:20.325186+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}